Objective To analyze the clinical effect of Salmeterol/Fluticasone in the treatment of bronchial dilation combined with reversible airflow limitation, and to provide data support for the application of the program. Method 148 patients with bronchial dilation reversible airflow limitation from January 2012 to January 2016 in our hospital were randomly divided into observation group and control group, 74 cases in each group. The routine treatment were given oxygen, bronchodilators, cough and phlegm, anti infection, observation group patients were treated with Salmeterol/Fluticasone propionate inhalation therapy. Compared the clinical symptoms score, pulmonary function, quality of life score and dyspnea score changes in two groups of patients, recorded within 6 months of treatment of acute episodes and observed the occurrence of adverse reactions during treatment in the two groups of patients. Result After treatment, the clinical symptoms, quality of life and dyspnea scores of the two groups were significantly lower than those before treatment (P < 0.05), and the indexes in observation group were significantly lower than those in control group (P < 0.05). After treatment, the forced expiratory volume in first second, forced vital capacity and peak expiratory flow in the two groups of patients were significantly higher than those before treatment (P < 0.05). The indexes in observation group were significantly higher than those in control group (P < 0.05). Within 6 months after treatment, the acute attack rate of bronchial dilation of observation group was significantly lower than that of control group (χ2 = 6.889, P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion The routine treatment combined with Salmeterol/Fluticasone propionate can promote early bronchiectasis with reversible airflow limitation in patients with clinical symptoms, improve lung function, reduce the rate of acute attacks without increasing the incidence of adverse reactions of risk.%目的 分析沙美特罗替卡松治疗支气管扩张症合并可逆性气流受限的临床疗效,为该方案的推广提供数据支持.方法 选取本院2012年1月至2016年1月收治的148例支气管扩张症合并可逆性气流受限患者为研究对象.采用随机数表法将入选患者分为观察组和对照组,每组各74例.两组患者均给予吸氧、扩张支气管、止咳化痰、抗感染等常规治疗,观察组患者加用沙美特罗替卡松吸入治疗.比较两组患者临床症状评分、生活质量评分、呼吸困难评分及肺功能变化,记录患者治疗6个月内急性发作次数和治疗期间不良反应发生情况.结果 治疗后两组患者临床症状评分、生活质量评分及呼吸困难评分较治疗前均显著降低(P<0.05),观察组患者上述指标均显著低于对照组(P<0.05).治疗后两组患者第一秒用力呼气量、用力肺活量及呼气流量峰值较治疗前均显著升高(P<0.05),观察组患者上述指标均显著高于对照组(P<0.05).治疗后6个月内观察组患者支气管扩张症急性发作率显著低于对照组(χ2=6.889,P<0.05).两组患者治疗期间不良反应发生率比较均无显著差异(P>0.05).结论 在常规治疗方案的基础上加用沙美特罗替卡松,能够在不增加不良反应发生风险的前提下,促进支气管扩张症合并可逆性气流受限患者临床症状和肺功能的改善,降低其急性发作率.
展开▼
